Krystal Biotech Plans for Second Commercial Gene Therapy Facility in Findlay Township, Pennsylvania

Specifications:

Name:

Krystal Biotech Plans for Second Commercial Gene Therapy Facility in Findlay Township, Pennsylvania

Location:

Pennsylvania

Company:

Krystal Biotech

Estimated Cost:

-

Source:

ir.krystalbio.com

Introduction:

Krystal Biotech, Inc., a gene therapy company developing medicines to treat rare diseases, announced the ground breaking of the second commercial gene therapy facility in Findlay Township, Pennsylvania.

Features:

The Findlay-based Current Good Manufacturing Practice (cGMP) facility, named ASTRA, will have the capacity to produce commercial gene therapy medicines to treat patients suffering from debilitating rare diseases.

The ASTRA facility is being designed as a state-of-the-art cGMP manufacturing facility that, beyond expanding Krystal's current production platform, will allow the in-house incorporation of raw material preparation, excipient manufacturing, testing, packaging, labeling and distribution, fully-integrating all components of the supply chain from starting materials to patient experience.

The ASTRA facility will initially be used as a commercial back up facility for B-VEC, which is being developed for the treatment of dystrophic epidermolysis bullosa, a rare and devastating skin disorder, and expand to produce investigational and commercial material for our pipeline products.

The 100,000 square foot facility will be built-out and validated over the next 12 -15 months. Opening the ASTRA facility will create about 75 new jobs in western Pennsylvania, with the potential to create upwards of 200 new jobs when at full capacity.